RxDoctor Payments Data

Sharan Rufus Ponniah

Interventional Cardiology · Canton, OHNPI 1659629657

Payments from drug & device makers

$8,101in general payments, 2019–2025

Across 122 payments — averaging $66.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$1K
  • Abbott$1K
  • W. L. Gore & Associates, Inc.$433
  • Abiomed$354
  • Edwards Lifesciences$306
  • plus $653 from 9 others

What the payments were for

  • Travel & lodging$2,91136%
  • Food & beverage$5,19064%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,101 in reported general payments places this provider in the 55th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$195,970
Medicare patients
521
Services billed
1,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$47,122
EntrestoSacubitril/Valsartan25$27,128
XareltoRivaroxaban19$19,936
Metoprolol Succinate142$1,430
Dofetilide12$1,335
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$1,122
Atorvastatin Calcium140$1,097
Ranolazine ErRanolazine12$930
ClopidogrelClopidogrel Bisulfate76$839
Bumetanide20$685
Carvedilol44$459
Potassium Chloride21$365
Rosuvastatin Calcium26$346
Losartan Potassium51$325
Isosorbide Mononitrate ErIsosorbide Mononitrate48$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$47,12243 claims
NovartisEntresto$11$27,12825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →